Davies, Andrew - University of Southampton

个人简介

Dr Davies is Senior Lecturer in Medical Oncology in the Cancer Sciences Division at the University of Southampton School of Medicine. He graduated in medicine with honours from the University of Southampton having also gained a first class Bachelor of Science degree. He went on to train in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK Clinical Fellow undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types. Dr Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody containing therapies applied to lymphoma and in the translation of biomarkers and novel therapies to the clinical arena. He is the principle investigator on a number of early phase clinical studies. Dr Davies has authored or co-authored numerous publications including those published in The Lancet Oncology, the Journal of Clinical Oncology, Blood and Haematologica.

研究领域

My major research interest is in the application translational studies and novel therapeutic approaches for patients with malignant lymphoma REMoDL-B: A randomised evaluation of molecular targeted therapy in diffuse large B-cell lymphoma with bortezomib (Peter Johnson). Phase III NCRI first line study in DLBCL (n=940). Gallium: An International phase III study evaluating the benefit of GA101 plus chemotherapy compared with rituximab plus chemotherapy in patients with advanced stage follicular lymphoma (n=1400). This will be the largest study ever conducted in this patient population and is a collaboration between the UK NCRI group, Roche and the German Low Grade Study Group. IELSG primary mediastinal B-cell lymphoma study: An international randomised phase III comparative study assessing the role of involved mediastinal radiotherapy after rituximab containing chemotherapy and following PET assessment. Anti CD19 DI-B4: Through the Cancer Research UK New Agents Committee (NAC) this will be a first in man phase I trial of a novel anti CD-19 monoclonal antibody in B-cell lymphoma and CLL Semprus PICC line study: Working with a biotech start-up company from MIT along with the Division of Infection, Inflammation and Immunity, The School of Engineering and PHLS, a first in man study of a novel coated indwelling intravenous catheters is funded and will include novel microbiological/physical endpoints. In addition, I am a co-Investigator, local PI, and member of the Trials Management Group of a number of CRUK funded studies Southampton LLR TAP Centre: I have led (PI) a successful grant bid for Southampton to become a Leukaemia and Lymphoma Research Therapies Acceleration Programme Centre, which will provide infrastructure for delivery of more early phase clinical trails in haematological malignancies.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

IL-4 enhances expression and function of surface IgM in CLL cells - Aguilar-Hernandez, Maria M., Blunt, Matthew, Dobson, Rachel, Yeomans, Alison, Thirdborough, Stephen, Larrayoz, Marta, Smith, Lindsay, Linley, Adam, Strefford, Jonathan C., Davies, Andrew, Johnson, Peter, Savelyeva, Natalia, Cragg, Mark, Forconi, Francesco, Packham, Graham, Stevenson, Freda K. and Steele, Andrew J. Published:2016Publication:BloodPage Range:1-25doi:10.1182/blood-2015-11-682906PMID:27002119 Letter. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma - Okosun, Jessica, Wolfson, Rachel, Wang, Jun, Araf, Shamzah, Wilkins, Lucy, Castellano, Brian, Escudero-Ibarz, Leire, Al Seraihi, Ahad Fahad, Seraihi, Al, Richter, Julia, Bernhart, Stephan, Efeyan, Alejo, Iqbal, Sameena, Matthews, Janet, Clear, Andrew, Afonso Guerra-Assunção, José, Bödör, Csaba, Quentmeier, Hilmar, Mansbridge, Christopher, Johnson, Peter, Davies, Andrew, Strefford, Jon, Packham, Graham, Barrans, Sharon, Jack, Andrew, Du, Ming-Qing, Calaminici, Maria, Lister, T Andrew, Auer, Rebecca, Montoto, Silvia, Gribben, John, Siebert, Reiner, Chelala, Claude, Zoncu, Roberto, Sabatini, David and Fitzgibbon, Jude Published:2015Publication:Nature GeneticsVolume:48, (2)Page Range:183-188doi:10.1038/ng.3473PMID:26691987 Evaluation of high-throughput genomic assays for the Fc Gamma Receptor Locus - Hargreaves, Chantal, Iriyama, C., Rose-Zerilli , Matthew, Nagelkerke, S.Q., Hussain, Khiyam, Ganderton, R., Lee, C., Kuijpers, T.W., Potter, Nora, Coupland, S., Davies, Andrew, Stackpole, M., Oates, M., Pettitt, A.R., Glennie, Martin, Cragg, Mark and Strefford, Jon Published:2015Publication:PLoS ONEVolume:10, (11)Page Range:e0142379-[13pp]doi:10.1371/journal.pone.0142379PMID:26545243 Antagonistic Human Fc?RIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. - Roghanian, Ali, Teige, Ingrid, Mårtensson, Linda, Cox, Kerry L., Kovacek, Mathilda, Ljungars, Anne, Mattson, Jenny, Sundberg, Annika, Vaughan, Andrew T., Shah, Vallari, Smyth, Neil R., Sheth, Bhavwanti, Chan, H.T. Claude, Li, Zhan-Chun, Williams, Emily L., Manfredi, Giusi, Oldham, Robert J., Mockridge, C. Ian, James, Sonya A., Dahal, Lekh N., Hussain, Khiyam, Nilsson, Björn, Verbeek, J. Sjef, Juliusson, Gunnar, Hansson, Markus, Jerkeman, Mats, Johnson, Peter W.M., Davies, Andrew, Beers, Stephen A., Glennie, Martin J., Frendéus, Björn and Cragg, Mark S. Published:2015Publication:Cancer CellVolume:27, (4)Page Range:473-488doi:10.1016/j.ccell.2015.03.005PMID:25873171